Michel Fochesato

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The candidate vaccine HZ/su is being developed to prevent herpes-zoster disease (HZ). HZ occurrence is attributed to declines in varicella-zoster virus (VZV) specific T-cell immunity. HZ/su contains VZV antigen, gE, and Adjuvant System AS01B (liposome-based formulation of MPL and QS-21). In clinical trials, AS01B enhances CD4(+) T-cell responses to gE. In(More)
  • 1